Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Vinorelbine
Accession Number
DB00361  (APRD00101)
Type
Small Molecule
Groups
Approved, Investigational
Description

Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) 5. It was initially approved in the USA in 1990's for the treatment of NSCLC 13.

It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting 2.

A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug 7.

Structure
Thumb
Synonyms
  • 5'-Noranhydrovinblastine
  • Vinorelbin
  • Vinorelbina
  • Vinorelbine
  • Vinorelbinum
External IDs
KW 2307 base
Product Ingredients
IngredientUNIICASInChI Key
Vinorelbine tartrate253GQW851Q125317-39-7CILBMBUYJCWATM-KRQCOKQWSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NavelbineInjection10 mg/1mLIntravenousPierre Fabre Pharmaceuticals, Inc.2005-11-152021-10-31Us
NavelbineSolution10 mgIntravenousPierre Fabre Pharma Canada Inc1994-12-312012-10-01Canada
Vinorelbine InjectionSolutionIntravenousFresenius Kabi2009-03-31Not applicableCanada
Vinorelbine Injection, USPSolutionIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Vinorelbine Injection, USPSolutionIntravenousGeneric Medical Partners Inc2017-08-01Not applicableCanada
Vinorelbine TartrateInjection10 mg/1mLIntravenousPierre Fabre Laboratories2011-08-312014-06-01Us
Vinorelbine TartrateInjection10 mg/1mLIntravenousPierre Fabre Laboratories2005-11-152014-06-01Us
Vinorelbine Tartrate for InjectionSolutionIntravenousPfizer Canada Ulc2004-12-22Not applicableCanada
Vinorelbine Tartrate for InjectionSolutionIntravenousTEVA Canada Limited2007-05-09Not applicableCanada
Vinorelbine Tartrate Injection USPSolutionIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aj-vinorelbineSolutionIntravenousAgila Jamp Canada IncNot applicableNot applicableCanada
VinorelbineInjection, solution10 mg/1mLIntravenousActavis Pharma, Inc.2015-03-01Not applicableUs
VinorelbineInjection, solution, concentrate50 mg/5mLIntravenousTeva Parenteral Medicines, Inc.2003-03-012013-04-30Us
VinorelbineInjection, solution10 mg/1mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-09-012016-08-31Us
VinorelbineInjection, solution10 mg/1mLIntravenousSagent Pharmaceuticals2014-09-15Not applicableUs
VinorelbineInjection, solution, concentrate10 mg/1mLIntravenousTeva Parenteral Medicines, Inc.2003-03-012012-11-30Us
VinorelbineInjection, solution10 mg/1mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-09-012016-08-31Us
VinorelbineInjection, solution10 mg/1mLIntravenousBedford Pharmaceuticals2004-02-112012-12-31Us
VinorelbineInjection50 mg/5mLIntravenousIngenus Pharmaceuticals, LLC2019-08-08Not applicableUs
VinorelbineInjection, solution10 mg/1mLIntravenousMylan Institutional2012-09-012016-08-31Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
International/Other Brands
Bendarelbin (Bendalis) / Eberelbin (Ebewe) / Eunexon (AC Farma) / Eurovinorelbin (Lapharm) / Filcrin (Filaxis) / Navelbin (Pierre Fabre) / Navildez (Cryopharma) / Navin (Cancernova) / Navirel (medac) / Neocitec (Sandoz) / Renovel (Mustafa Nevzat) / Riborelbin (Ribosepharm) / Vilne (Dosa) / Vinelbine (GP-Pharm) / Vinorayne (Hospira) / Vinorel (Eriochem) / Vinorgen (Bago) / Vinotel (Fresenius) / Zinavin (Novamed)
Categories
UNII
Q6C979R91Y
CAS number
71486-22-1
Weight
Average: 778.947
Monoisotopic: 778.394164715
Chemical Formula
C45H54N4O8
InChI Key
GBABOYUKABKIAF-IELIFDKJSA-N
InChI
InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1
IUPAC Name
methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0^{3,11}.0^{4,9}]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2,4,6,13-tetraene-10-carboxylate
SMILES
[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC

Pharmacology

Indication

Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs 5.

Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents 14.

For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate 14.

For the treatment of recurrent or metastatic squamous cell head and neck cancer 14.

For the treatment of recurrent ovarian cancer 14.

For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy 14.

For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus 14.

Associated Conditions
Pharmacodynamics

Vinorelbine is a semi-synthetic vinca-alkaloid with a wide spectrum of anti-tumor activity. The vinca-alkaloids are considered spindle poisons. They work by interfering with the polymerization of tubulin, a protein responsible for building the microtubule system which appears during cell division in proliferating cancer cells 11.

Mechanism of action

Vinca alkaloids are structurally similar compounds composed of two multi-ringed units, vindoline, and catharanthine. Vinorelbine tartrate is a vinca alkaloid in which the catharanthine component is the target of structural modification 9, 10.

This structural modification contributes to unique pharmacologic properties.The antitumor activity of vinorelbine tartrate is believed to be owed to the inhibition of mitosis at metaphase via its interaction with tubulin 5.

Vinorelbine is a mitotic spindle poison that interferes with chromosomal segregation during mitosis, also known as cell division. It pauses cells at the G2/M phases, when present at concentrations close to the half maximal inhibitory concentration (IC50). Microtubules, which are derived from polymers of tubulin, are the main target of vinorelbine.

The chemical modification used to produce vinorelbine allows for the opening of the eight-member catharanthine ring with the formation of both a covalent and reversible bond with tubulin 11.

The relative contribution of different microtubule-associated proteins in the production of tubulin vary between neural tissue and proliferating cells and this has important functional implications. The ability of vinorelbine to bind specifically to mitotic rather than other microtubules has been shown and may suggest that neurotoxicity is less likely to be a problem than with the molecular mechanism of action 11.

As with other anti-microtubule agents, vinorelbine is known to contribute apoptosis in malignant cells. The exact mechanisms by which this process occurs are complex and many details are yet to be elucidated. The disarray of the microtubule structure has a number of effects, including the induction of tumor suppressor gene p53 and activation/inactivation of a number of protein kinases involved in essential signaling pathways, including p21 WAF1/CIP1 and Ras/Raf, PKC/PKA. These molecular changes lead to phosphorylation and consequently inactivation of the apoptosis inhibitor Bcl2. This, in turn, results in a decrease in the formation of heterodimers between Bcl2 and the pro-apoptotic gene BAX, stimulating the sequence of cell apoptosis 11.

Vinorelbine tartrate also possibly interferes with amino acid, cyclic AMP and glutathione metabolism, calmodulin-dependent Ca++-transport ATPase activity, cellular respiration, and nucleic acid and lipid biosynthesis 5.

TargetActionsOrganism
ATubulin beta chain
antagonist
inhibitor
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Vinorelbine is rapidly absorbed with peak serum concentration reached within 2 hours 5.

Vinorelbine is highly bound to platelets and lymphocytes and is also bound to alpha 1-acid glycoprotein, albumin, and lipoproteins 4.

Volume of distribution

The volume of distribution is large, indicating extensive extravascular distribution 4.

The steady-state volume of distribution values range from 25.4 to 40.1 L/kg, according to one study 7.

Widely distributed, with highest amounts found in elimination organs such as liver and kidneys, minimal in heart and brain 7.

Protein binding

80-90% 6

Metabolism

Vinorelbine undergoes substantial hepatic elimination in humans. Two metabolites of vinorelbine have been identified in human blood, plasma, and urine; vinorelbine N-oxide and deacetylvinorelbine. Deacetylvinorelbine has been demonstrated to be the primary metabolite of vinorelbine in humans, and has been shown to possess antitumor activity similar to vinorelbine 9, 10.

Vinorelbine is metabolized into two other minor metabolites, 20'-hydroxyvinorelbine and vinorelbine 6'-oxide 10.

Therapeutic doses of vinorelbine (30 mg/m2) yield very small, if any, quantifiable levels of either metabolite in blood or urine. The metabolism of vinorelbine is mediated by hepatic cytochrome P450 isoenzymes in the CYP3A subfamily 8, 4.

As the liver provides the main route for metabolism of the drug, patients with hepatic impairment may demonstrate increased toxicity with standard dosing, however, there are no available data on this. Likewise, the contribution of cytochrome P450 enzyme action to vinorelbine metabolism has potential implications in patients receiving other drugs metabolized by this route 11.

Route of elimination

Vinorelbine undergoes substantial hepatic elimination in humans, with large amounts recovered in feces after intravenous administration to humans 5.

Urinary excretion of unchanged drug accounts for less than 20% of an intravenous dose, with fecal elimination accounting for an additional 30% to 60% 4.

After intravenous administration of radioactive vinorelbine, approximately 18% and 46% of administered radioactivity was recovered in urine and feces, respectively 7.

Half life

The terminal phase half-life averaged 27.7 to 43.6 hours; the mean plasma clearances ranged from 0.97 to 1.26 L/hr/kg 4.

Clearance

The plasma clearance of vinorelbine is high, approaching the same as hepatic blood flow in humans, and its volume of distribution is large, indicating extensive extravascular distribution. In comparison to vinblastine or vincristine 4.

The clearance was found to be in the range of 0.29-1./26 L/ per kg in 4 clinical trials of patients receiving 30 mg/m2 of vinorelbine 12.

Toxicity

Due to the wide array of adverse effects of this drug, the toxicity of is categorized into organ systems 5.

Hematologic: Granulocytopenia was the primary dose-limiting toxicity with vinorelbine tartrate therapy; it is generally reversible and not cumulative. In one study, granulocytopenia resulted in hospitalizations for fever and/or sepsis in 8% of NSCLC and 9% of breast cancer patients 5. Infectious (septic) deaths occurred in about 1% of patients. Grade 3 or 4 anemia occurred in about 1% of lung cancer and approximately 14% of breast cancer patients. Blood transfusions were administered to 18% of patients who received vinorelbine tartrate therapy. The incidence of Grade 3 and 4 thrombocytopenia was found to be less than 1% 5.

Neurologic: Mild to moderate peripheral neuropathy may occur. Symptoms of paresthesia and hypesthesia are reported as the most commonly reported neurologic toxicities of this drug. The loss of deep tendon reflexes (DTR) occurs in less than 5% of patients, according to one study. The development of severe peripheral neuropathy is rare 5.

Dermatologic: Alopecia has been reported in only about 12% of patients and is usually reported as mild. Vinorelbine tartrate is a moderate vesicant, leading to injection site reactions. Symptoms include erythema, pain at the injection site and vein discoloration occurred in about 1/3 of all patients. Chemical phlebitis along the vein, near the site of injection, has been reported 5.

Respiratory: Shortness of breath was reported in 3% of NSCLC and 9% of breast cancer patients, and was severe in 2% of each patient population. Interstitial pulmonary changes have been documented in a few patients 5.

Gastrointestinal: Mild or moderate nausea symptoms occurred in 32% of NSCLC and 47% of breast cancer patients treated with vinorelbine tartrate. Severe nausea was occurred infrequently (1% and 3% in NSCLC and breast cancer patients, respectively). Prophylactic administration of anti-emetics was not routine in patients treated with single-agent vinorelbine tartrate. Constipation occurred in about 28% of NSCLC and 38% of breast cancer patients. The paralytic ileus incidence of less than 2% of patients. Vomiting, diarrhea, anorexia and stomatitis were found to be mild or moderate and occurred in less than 20% of study patients 5.

Hepatic: Transient elevations of liver enzymes were reported without clinical symptoms. Cardiovascular: Chest pain was reported in 5% of NSCLC and 8% of breast cancer patients. Most reports of chest pain were in patients who had either a history of cardiovascular disease or tumor within the chest. There have been rare reports of myocardial infarction; however, these have not been shown definitely attributable to vinorelbine tartrate 8.

Other: Muscle weakness (asthenia) occurred in about 25% of patients with NSCLC and 41% of patients with breast cancer. It was usually mild or moderate but showed a linear increase with cumulative doses 8.

Several other toxicities reported in approximately 5% of patients include jaw pain, myalgia, arthralgia, headache, dysphagia, and skin rash. Hemorrhagic cystitis (bladder inflammation with blood in urine) and the syndrome of inappropriate ADH secretion were both reported in less than 1% of patients. The treatment of these entities are mainly symptomatic 8.

The carcinogenic potential of Vinorelbine has not been adequately studied. Vinorelbine has been demonstrated to affect chromosome number and likely the chromosome structure in vivo (polyploidy in bone marrow cells from Chinese hamsters and a positive micronucleus test in mice were observed) 8.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Vinorelbine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Vinorelbine is combined with 2-Methoxyethanol.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Vinorelbine.
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Vinorelbine.
6-Deoxyerythronolide BThe serum concentration of Vinorelbine can be increased when it is combined with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Vinorelbine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Abatacept.
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Vinorelbine.
AbemaciclibThe serum concentration of Vinorelbine can be increased when it is combined with Abemaciclib.
AbetimusThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Abetimus.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Vinorelbine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C: Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol. 2001 Nov;12(11):1643-9. [PubMed:11822766]
  2. Piccirillo MC, Daniele G, Di Maio M, Bryce J, De Feo G, Del Giudice A, Perrone F, Morabito A: Vinorelbine for non-small cell lung cancer. Expert Opin Drug Saf. 2010 May;9(3):493-510. doi: 10.1517/14740331003774078. [PubMed:20350282]
  3. Bahadori F, Topcu G, Eroglu MS, Onyuksel H: A new lipid-based nano formulation of vinorelbine. AAPS PharmSciTech. 2014 Oct;15(5):1138-48. doi: 10.1208/s12249-014-0146-3. Epub 2014 May 29. [PubMed:24871553]
  4. Wargin WA, Lucas VS: The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol. 1994 Oct;21(5 Suppl 10):21-7. [PubMed:7973765]
  5. Vinorelbine Tartrate [Link]
  6. Vinorelbine, Ontario Cancer Care [Link]
  7. Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer [Link]
  8. Vinorelbine injection, Daily Med [Link]
  9. Metabolism pathway of vinorelbine (Navelbine®) in human: Characterisation of the metabolites by HPLC–MS/MS [Link]
  10. Vinca Alkaloid Pharmacokinetics [Link]
  11. Vinorelbine, a clinical review [Link]
  12. Vinorelbine FDA pharmacology review [Link]
  13. Drug Approval Package [Link]
  14. Navelbine, PDR [Link]
External Links
Human Metabolome Database
HMDB0014505
KEGG Drug
D08680
PubChem Compound
44424639
PubChem Substance
46507772
ChemSpider
4470974
ChEBI
480999
ChEMBL
CHEMBL553025
Therapeutic Targets Database
DAP000765
PharmGKB
PA451881
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Vinorelbine
ATC Codes
L01CA04 — Vinorelbine
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (102 KB)
MSDS
Download (155 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceBreast Cancer1
1CompletedPreventionLeukemias / Multiple Myeloma (MM)1
1CompletedTreatmentAdvanced Malignant Solid Tumors1
1CompletedTreatmentAdvanced Neoplasm1
1CompletedTreatmentBladder Cancers / Cervical Cancers / Endometrial Cancer / Vaginal Cancers1
1CompletedTreatmentBreast Cancer4
1CompletedTreatmentBreast Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentBreast Cancer / Lung Cancers / Malignancies / Ovarian Cancer1
1CompletedTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Hereditary Breast/Ovarian Cancer - BRCA1 / Hereditary Breast/Ovarian Cancer - BRCA2 / Male Breast Cancer / Progesterone Receptor-negative Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
1CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Hereditary Paraganglioma / Male Breast Cancer / Metastatic Gastrointestinal Carcinoid Tumor / Metastatic Pheochromocytoma / Non-Small Cell Lung Cancer Recurrent / Pancreatic Polypeptide Tumor / Paraganglion neoplasm malignant / Recurrent Breast Cancer / Recurrent Cervical Cancer / Recurrent Endometrial Carcinoma / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Islet Cell Carcinoma / Recurrent Neuroendocrine Carcinoma of the Skin / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Pheochromocytoma / Recurrent Prostate Cancer / Recurrent Uterine Sarcoma / Refractory Small cell lung cancer / Regional Gastrointestinal Carcinoid Tumor / Regional Pheochromocytoma / Renal Cell Cancer, Recurrent / Stage III Cervical Cancer / Stage III Endometrial Carcinoma / Stage III Neuroendocrine Carcinoma of the Skin / Stage III Ovarian Epithelial Cancer / Stage III Ovarian Germ Cell Tumor / Stage III Prostate Cancer / Stage III Renal Cell Cancer / Stage III Uterine Sarcoma / Stage IIIA Breast Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Breast Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Endometrial Carcinoma / Stage IV Neuroendocrine Carcinoma of the Skin / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Prostate Cancer / Stage IV Renal Cell Cancer / Stage IV Uterine Sarcoma / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer / Thyroid Gland Medullary Carcinoma1
1CompletedTreatmentLeukemias1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)6
1CompletedTreatmentLung Cancers1
1CompletedTreatmentMalignant Lymphomas1
1CompletedTreatmentMetastatic Breast Cancer1
1CompletedTreatmentNeoplasms2
1CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1Not Yet RecruitingTreatmentPediatric Cancer1
1RecruitingTreatmentHER2-expressing Cancers1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Pleural Mesothelioma (MPM)1
1RecruitingTreatmentMetastatic Breast Cancer1
1TerminatedTreatmentBreast Cancer1
1TerminatedTreatmentFailure or Contraindication of Trastuzumab Therapy / First or Second Line Therapy / HER2 Positive / Metastatic Breast Cancer1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1TerminatedTreatmentMalignant Solid Tumours1
1TerminatedTreatmentMetastatic Breast Cancer / Metastatic Non Small Cell Lung Cancer1
1Unknown StatusTreatmentAdvanced Solid Tumors1
1Unknown StatusTreatmentLung Cancers1
1Unknown StatusTreatmentLymphoma, Hodgkins1
1Unknown StatusTreatmentNonhematologic Malignancies1
1Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentAdvanced Malignant Solid Tumors / Breast Cancer1
1, 2CompletedTreatmentBreast Cancer3
1, 2CompletedTreatmentBreast / Malignancies1
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1, 2CompletedTreatmentLung Cancers1
1, 2CompletedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentMetastatic Breast Cancer1
1, 2CompletedTreatmentMetastatic Cancers1
1, 2CompletedTreatmentProstate Cancer1
1, 2Not Yet RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT)1
1, 2RecruitingTreatmentAdvanced Solid Tumours / Breast Cancer / Cervix Cancer / Head and Neck Carcinoma / Prostate Cancer1
1, 2RecruitingTreatmentMalignancies1
1, 2TerminatedTreatmentBreast Cancer1
1, 2TerminatedTreatmentBreast Cancer / Cancer, Advanced / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Pancreas / Ovarian / Sarcomas1
1, 2TerminatedTreatmentBreast Cancer / Metastatic Breast Cancer1
1, 2TerminatedTreatmentLung Cancers1
1, 2TerminatedTreatmentStage IV (Metastatic) Breast Cancer1
1, 2Unknown StatusTreatmentMetastatic Breast Cancer1
2Active Not RecruitingTreatmentBreast Cancer2
2Active Not RecruitingTreatmentLocally Advanced Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentLung Cancers1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMalignant Tumor of the Breast / Neoplasms, Breast1
2Active Not RecruitingTreatmentMesothelioma1
2Active Not RecruitingTreatmentMetastatic Breast Cancer3
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Lymphocyte Predominant Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Pleomorphic Rhabdomyosarcoma / Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Rhabdomyosarcoma1
2CompletedTreatmentAdvanced Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB1
2CompletedTreatmentBRMS1 / Patient With a Maximum of One Chemotherapy / Patient With Progression After Taxanes / Performance Status Zero to Two for Beginning the Study1
2CompletedTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Sarcomas1
2CompletedTreatmentBreast Cancer17
2CompletedTreatmentBreast Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Prostate Cancer1
2CompletedTreatmentBreast Cancer / Neoplasms Metastasis1
2CompletedTreatmentBreast Cancer / Stage II Breast Cancer / Stage III Breast Cancer1
2CompletedTreatmentCancer of the Lung / Carcinoma NOS / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung1
2CompletedTreatmentCarcinoma Breast Stage IV1
2CompletedTreatmentCervical Cancers1
2CompletedTreatmentConcomitant Radiochemotherapy / NSCLC Stage IIIB1
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Her2-Positive Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2CompletedTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentHER-2 Positive Breast Cancer1
2CompletedTreatmentHer2-negative Locally Advanced Breast Cancer / Her2-negative Metastatic Breast Cancer1
2CompletedTreatmentHodgkins Disease (HD)1
2CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Hodgkin Disease / Lymphoma, Hodgkins / Malignant Lymphomas1
2CompletedTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)2
2CompletedTreatmentLow-Grade Gliomas1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)17
2CompletedTreatmentLung Cancers8
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentMalignancies2
2CompletedTreatmentMalignant Lymphomas3
2CompletedTreatmentMalignant Pleural Mesothelioma (MPM)1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentMesothelioma1
2CompletedTreatmentMetastatic Breast Cancer5
2CompletedTreatmentMetastatic Melanoma1
2CompletedTreatmentNeoplasms Metastasis / Neoplasms, Breast1
2CompletedTreatmentNeoplasms, Breast4
2CompletedTreatmentNeoplasms, Lung1
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (CD20+)1
2CompletedTreatmentNon-Small Cell Lung Cancer Recurrent / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentPlasma Cell Myeloma1
2CompletedTreatmentProstate Cancer4
2CompletedTreatmentRenal Cancers1
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2Not Yet RecruitingTreatmentCirculating Tumor DNA / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2Not Yet RecruitingTreatmentFallopian Tube Cancer / Ovarian Cancer1
2Not Yet RecruitingTreatmentGM-CSF / Lung Cancer Non-Small Cell Cancer (NSCLC) / SBRT1
2Not Yet RecruitingTreatmentHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast1
2Not Yet RecruitingTreatmentMetastatic Breast Cancer3
2Not Yet RecruitingTreatmentNon-small Cell Lung Cancer Stage Ⅱ / Non-small Cell Lung Cancer Stage ⅢA1
2Not Yet RecruitingTreatmentPathologic Residual Cancer Cells1
2Not Yet RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentAdenocarcinoma of the Lung1
2RecruitingTreatmentAdvanced Non Small Cell Lung Cancer / Advanced Non Squamous Non Small Cell Lung Cancer1
2RecruitingTreatmentAdvanced Triple-Negative Breast Cancer1
2RecruitingTreatmentAdvanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers / Tumors, Solid1
2RecruitingTreatmentAggressive Non-Hodgkin Lymphoma1
2RecruitingTreatmentAmyloidosis / Multiple Myeloma (MM)1
2RecruitingTreatmentAnaplastic Large Cell Lymphoma / Vinorelbine2
2RecruitingTreatmentBreast Cancer3
2RecruitingTreatmentBreast Cancer / Metastatic Brain Tumors1
2RecruitingTreatmentCarcinoma, Small Cell / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neuroendocrine Tumors / Ovarian Epithelial Cancer / Small Cell Lung Carcinoma1
2RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
2RecruitingTreatmentEffects of Chemotherapy / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentHER2 Positive Breast Cancers1
2RecruitingTreatmentHormone Receptor Positive Advanced Breast Cancer1
2RecruitingTreatmentLarge Cell Lung Carcinoma Metastatic / Lung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Lung Adenocarcinoma / Metastatic Lung Cancer1
2RecruitingTreatmentLow-Grade Gliomas1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2RecruitingTreatmentLung neoplasm malignant1
2RecruitingTreatmentLymphoma, Hodgkins / Relapsed or Refractory Hodgkin Lymphoma1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentMalignant Neoplasm of Colon1
2RecruitingTreatmentMetastatic Breast Cancer3
2RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
2RecruitingTreatmentMultiple Myeloma (MM)1
2RecruitingTreatmentNeoplasms, Breast1
2RecruitingTreatmentNeoplasms, Head and Neck1
2RecruitingTreatmentNon-small Cell Lung Cancer Stage IIIA1
2RecruitingTreatmentNon-small Cell Lung Cancer Stage IIIA / Radiotherapy1
2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2RecruitingTreatmentSquamous Cell Esophageal Carcinoma1
2TerminatedTreatmentAdvanced Stage IIIB / High Thymidylate Synthase Expression / Lung Cancer Non-Small Cell Cancer (NSCLC) / Secondary1
2TerminatedTreatmentBreast Cancer8
2TerminatedTreatmentBreast Cancer / Metastatic Breast Cancer1
2TerminatedTreatmentCarcinoma Breast Stage IV1
2TerminatedTreatmentEarly Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
2TerminatedTreatmentMesothelioma1
2TerminatedTreatmentMetastatic Breast Cancer1
2TerminatedTreatmentNeoplasms, Breast2
2TerminatedTreatmentTriple Negative Breast Cancer (TNBC)1
2Unknown StatusDiagnosticLung Cancers1
2Unknown StatusSupportive CareChemotherapeutic Agent Toxicity / Fatigue / Lung Cancers / Musculoskeletal Complications1
2Unknown StatusTreatmentBreast Cancer2
2Unknown StatusTreatmentEwing's Tumor / Medulloblastomas / Neoplasms, Connective and Soft Tissue / Neuroblastomas / Rhabdomyosarcomas / Sarcoma, Osteogenic1
2Unknown StatusTreatmentInfiltrating Duct and Lobular Carcinoma In Situ / Inflammatory Breast Carcinoma / Invasive Lobular Breast Carcinoma1
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
2Unknown StatusTreatmentLung Cancers3
2Unknown StatusTreatmentLymphoma, Hodgkins1
2Unknown StatusTreatmentMesothelioma, Malignant2
2Unknown StatusTreatmentMetastatic Breast Cancer1
2Unknown StatusTreatmentProstate Cancer1
2WithdrawnTreatmentMalignant Lymphomas1
2WithdrawnTreatmentNeoplasms, Breast1
2WithdrawnTreatmentProstate Cancer1
2, 3Active Not RecruitingSupportive CareMalignancies1
2, 3CompletedTreatmentLung Cancers1
2, 3Not Yet RecruitingTreatmentBreast Cancer / Chemotherapy Effect / Disease-Free Survival1
2, 3TerminatedTreatmentBreast Cancer1
2, 3TerminatedTreatmentBreast Cancer / HER2 Positive Breast Cancers1
2, 3TerminatedTreatmentMetastatic Breast Cancer1
3Active Not RecruitingTreatmentBreast Cancer2
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentChildhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentHER-2 Positive Breast Cancer / Neoplasms, Metastatic1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
3Active Not RecruitingTreatmentLung Cancers1
3Active Not RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
3Active Not RecruitingTreatmentPleural Mesothelioma Malignant Advanced1
3Active Not RecruitingTreatmentStage IB Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v71
3CompletedPreventionMalignancies1
3CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage IVB Cervical Cancer1
3CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
3CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
3CompletedTreatmentBreast Cancer2
3CompletedTreatmentBreast Cancer / Cancer of the Breast / HER2-Negative Breast Cancer / Triple Negative Breast Cancer (TNBC) / Tumors, Breast1
3CompletedTreatmentBreast Cancer / Neoplasms Metastasis1
3CompletedTreatmentBreast Cancer / Stage IV Breast Cancer1
3CompletedTreatmentHER2/Neu Over-expressing Locally Advanced Breast Cancer / Metastatic Breast Cancer1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)9
3CompletedTreatmentLung Cancers8
3CompletedTreatmentMesothelioma, Malignant1
3CompletedTreatmentMetastatic Breast Cancer1
3CompletedTreatmentNeoplasms, Breast1
3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
3Not Yet RecruitingTreatment2-year Disease-Free Survival1
3Not Yet RecruitingTreatmentChemotherapy Effect / Susceptibility, Genetic1
3Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Hydrothorax1
3RecruitingTreatmentBotryoid-Type Embryonal Rhabdomyosarcoma / Rhabdomyosarcoma, Alveolar / Rhabdomyosarcoma, Embryonal / Rhabdomyosarcomas / Sclerosing Rhabdomyosarcoma / Spindle Cell Rhabdomyosarcoma / Untreated Childhood Rhabdomyosarcoma1
3RecruitingTreatmentBreast Cancer1
3RecruitingTreatmentBreast Cancer / Breast Cancer Model / Effects of Chemotherapy1
3RecruitingTreatmentBreast Cancer / Metastasis1
3RecruitingTreatmentCarcinoma, Bronchogenic / Chronic Lung Diseases / Neoplasm, Bronchial / Neoplasms / Neoplasms, Lung / Respiratory Tract Diseases / Respiratory Tract Neoplasms / Stage IV, NSCLC / Thoracic Neoplasms1
3RecruitingTreatmentCompletely Resected NSCLC With Common EGFR Mutations1
3RecruitingTreatmentEGFR / Lung Cancer Non-Small Cell Cancer (NSCLC)1
3RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Esophagus / Squamous Cell Carcinoma of Esophagus1
3RecruitingTreatmentHER2-positive Locally Advanced or Metastatic Breast Cancer1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
3RecruitingTreatmentMetastatic Breast Cancer3
3RecruitingTreatmentNon-small Cell Lung Cancer Stage IIIA / Radiotherapy1
3RecruitingTreatmentStage Ib Lung Carcinoma1
3TerminatedNot AvailableStage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
3TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer1
3TerminatedTreatmentMalignant Lymphomas1
3Unknown StatusTreatmentBreast Cancer1
3Unknown StatusTreatmentCarcinoma, Invasive Ductal, Breast1
3Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Unknown StatusTreatmentLung Cancers4
3Unknown StatusTreatmentSarcomas1
3WithdrawnOtherAdvanced Breast Cancer / Her2-Positive Breast Cancer1
3WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3WithdrawnTreatmentLung Cancers1
4CompletedTreatmentBreast Cancer1
4CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
4CompletedTreatmentMetastatic Non-Small Cell Lung Cancer1
4RecruitingTreatmentMetastatic Breast Cancer1
4RecruitingTreatmentPrimary Breast Cancer1
Not AvailableAvailableNot AvailableMetastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation / Triple-Negative Breast Cancer (TNBC)1
Not AvailableCompletedNot AvailableBreast Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableCompletedNot AvailableBreast Cancer / Metastatic Cancers1
Not AvailableCompletedNot AvailableMalignancies1
Not AvailableCompletedTreatmentBreast Cancer1
Not AvailableCompletedTreatmentHypermethylation / Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC)1
Not AvailableCompletedTreatmentLung Cancers1
Not AvailableNot Yet RecruitingNot AvailableImmune-Related Adverse Events / Lung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableNot Yet RecruitingTreatmentHER2 Positive Breast Cancers1
Not AvailableRecruitingNot AvailableBreast Cancer / Neoplasms, Breast1
Not AvailableTerminatedNot AvailableBreast Cancer1
Not AvailableUnknown StatusNot AvailableLung Cancer Small Cell Lung Cancer (SCLC)1

Pharmacoeconomics

Manufacturers
  • Pierre fabre medicament
  • Actavis totowa llc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Ebewe pharma ges mbh nfg kg
  • Hospira inc
  • Teva parenteral medicines inc
Packagers
  • APP Pharmaceuticals
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Ebewe Pharma
  • Hospira Inc.
  • Pierre Fabre
  • Sagent Pharmaceuticals
  • Sicor Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Wyeth Pharmaceuticals
Dosage forms
FormRouteStrength
SolutionIntravenous10 mg
InjectionIntravenous50 mg/5mL
Injection, solution, concentrateIntravenous10 mg/1mL
Injection, solution, concentrateIntravenous50 mg/5mL
InjectionIntravenous10 mg/1mL
Injection, solutionIntravenous10 mg/1mL
SolutionIntravenous
Prices
Unit descriptionCostUnit
Navelbine 50 mg/5 ml vial42.0USD ml
Vinorelbine 50 mg/5 ml vial27.6USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)181-183MSDS
water solubility10 mg/mL in waterMSDS
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0122 mg/mLALOGPS
logP4.39ALOGPS
logP4.65ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)10.87ChemAxon
pKa (Strongest Basic)8.66ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area133.87 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity216.99 m3·mol-1ChemAxon
Polarizability84.31 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.974
Blood Brain Barrier-0.8815
Caco-2 permeable+0.5602
P-glycoprotein substrateSubstrate0.9283
P-glycoprotein inhibitor IInhibitor0.7488
P-glycoprotein inhibitor IIInhibitor0.7388
Renal organic cation transporterNon-inhibitor0.6979
CYP450 2C9 substrateNon-substrate0.8513
CYP450 2D6 substrateSubstrate0.6471
CYP450 3A4 substrateSubstrate0.7247
CYP450 1A2 substrateNon-inhibitor0.8415
CYP450 2C9 inhibitorNon-inhibitor0.7863
CYP450 2D6 inhibitorNon-inhibitor0.8369
CYP450 2C19 inhibitorNon-inhibitor0.8381
CYP450 3A4 inhibitorNon-inhibitor0.8095
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6672
Ames testNon AMES toxic0.8064
CarcinogenicityNon-carcinogens0.9299
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8350 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9014
hERG inhibition (predictor II)Non-inhibitor0.5171
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
Inhibitor
General Function
Ubiquitin protein ligase binding
Specific Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name
TUBB
Uniprot ID
P07437
Uniprot Name
Tubulin beta chain
Molecular Weight
49670.515 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J, Hill BT: Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol. 1998 Mar 1;55(5):635-48. [PubMed:9515574]
  4. Chang AY, Garrow GC: Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol. 1995 Apr;22(2 Suppl 5):66-70; discussion 70-1. [PubMed:7740336]
  5. Seve P, Dumontet C: [Class III beta tubulin expression in nonsmall cell lung cancer]. Rev Mal Respir. 2010 Apr;27(4):383-6. doi: 10.1016/j.rmr.2010.03.006. Epub 2010 Mar 25. [PubMed:20403547]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Leveque D, Wisniewski S, Renault C, Peter JD, Le Corre P, Monteil H, Jehl F: The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. Anticancer Res. 2003 May-Jun;23(3B):2741-4. [PubMed:12894568]
  2. Beulz-Riche D, Grude P, Puozzo C, Sautel F, Filaquier C, Riche C, Ratanasavanh D: Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53. doi: 10.1111/j.1472-8206.2005.00367.x. [PubMed:16176333]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Le Guellec C, Lacarelle B, Catalin J, Durand A: Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5. [PubMed:8258200]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]

Drug created on June 13, 2005 07:24 / Updated on December 11, 2019 03:26